Comparative Pharmacology
Head-to-head clinical analysis: DYANAVEL XR 15 versus QUILLICHEW ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYANAVEL XR 15 versus QUILLICHEW ER.
DYANAVEL XR 15 vs QUILLICHEW ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dyanavel XR contains amphetamine, which is a central nervous system stimulant that increases synaptic concentrations of dopamine and norepinephrine by inhibiting their reuptake and promoting their release from presynaptic terminals.
Quillichew ER contains methylphenidate, a central nervous system (CNS) stimulant. The mechanism of action in ADHD is not fully understood, but it is thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron, increasing their availability in the extraneuronal space.
1-3 capsules orally once daily in the morning. Each capsule contains 15 mg of amphetamine (equivalent to 15 mg dextroamphetamine/amphetamine).
Initial 20 mg orally once daily, titrate by 10 mg weekly to maximum 60 mg/day (methylphenidate component).
None Documented
None Documented
Terminal elimination half-life: amphetamine (d-isomer) 9-11 hours, l-isomer 11-14 hours; allows for once-daily dosing in extended-release formulation
The terminal elimination half-life of methylphenidate is approximately 3-4 hours in children and 3.5-5 hours in adults. For QuilliChew ER, the extended-release formulation provides a prolonged absorption phase, with an effective duration of action of up to 12 hours.
Renal (80-90% as unchanged drug and metabolites, primarily dehydro-amphetamine); fecal excretion minimal (<5%)
QuilliChew ER (methylphenidate extended-release chewable tablet) is primarily eliminated via renal excretion as metabolites (60-80%) and unchanged drug (approx. 10%). Hepatic metabolism accounts for the remainder. Fecal elimination is minimal.
Category C
Category C
CNS Stimulant
CNS Stimulant